ST. LOUIS & NEW YORK--(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s participation in Express Scripts’ rebate program. Due to improved terms under the agreement, Express Scripts has added Lipitor® (atorvastatin calcium), Pfizer’s treatment for high cholesterol and the reduction of heart attack and stroke, to its national preferred formulary, effective June 1. The terms of the agreement were not disclosed.
